Navigation Links
2008 Sees Significant Rise in Prescription Abandonment and Uptake of Generics
Date:4/7/2009

New Data Show U.S. Rx Abandonment Rate Up 34 Percent Since 2006; Generics Led Brands By a Billion Prescriptions in 2008

BRIDGEWATER, N.J., April 7 /PRNewswire/ -- Wolters Kluwer Health, a leading provider of information and business intelligence for students, professionals and institutions in medicine, nursing, allied health, pharmacy and the pharmaceutical industry, today released its annual analysis of the U.S. pharmaceutical market that shows an increased rate of prescription abandonment among consumers. A prescription is defined as abandoned when a patient submits a retail prescription to a pharmacy but never actually picks it up.

Looking at U.S. commercial plan claims for 2008, Wolters Kluwer Health found that prescription abandonment increased by 34 percent nationally compared to 2006 --- jumping from an average of 5.15 percent in 2006 to 6.8 percent in 2008. It also found that abandonment increased as the amount of the co-pay increased, especially for new prescriptions. For example, new prescriptions with co-pays of $100 or more carry an abandonment rate of just over 20 percent; while with co-pays of $10 or under, the abandonment is only 4 percent.

"Price sensitivity is clearly a factor as consumers decide to forego certain prescriptions altogether, including some for chronic conditions," said Mark Spiers, President & CEO, Wolters Kluwer Health, Pharma Solutions. "This disturbing trend may have serious health implications and seems poised to continue especially if the economy deteriorates further."

Two-Thirds of Prescriptions Filled to be Generic by End of Year

The Wolters Kluwer Health analysis, known as Pharma Insight, also shows that generic medications continue to make significant gains over brands by grabbing more than 60 percent of all U.S. prescriptions filled in 2008, and an even greater percentage of the subset of drugs that are taken orally. According to the data, there were 2.4 billion prescriptions filled for generic drugs and only 1.4 billion for brand-name medications --- an unprecedented spread of a billion prescriptions.

According to the data, U.S. prescriptions for generics and brands reached equilibrium in 2005 and then generics continued to build momentum each year thereafter increasing at a compound annual growth rate (CAGR) of 12 percent since 2004. Conversely, branded drugs slowed pace to a negative 6 percent CAGR for the same period.

"We're close to the point, certainly by the end of 2009, where two-out-of-every-three prescriptions filled will be generic," continued Spiers. "These trends are going to become even more pronounced moving forward as there are many blockbusters in major therapeutic areas like cholesterol reducers due to come off patent in the coming three years. The volume of available generics will increase, and there are very few new 'blockbuster' drugs in the pipeline to replace them."

According to Spiers, many factors contribute to the steady growth of generic prescriptions in America, among the most prevalent: patient education, awareness and changing attitudes. "Patients are becoming far more comfortable with the concept of using a generic in place of a brand. This, in part, is due to patient education programs and enthusiasm forged by marketing vehicles such as $4 generic drug programs," said Spiers.

The data also suggest that the economy is playing an enormous role in patient decision-making. As third-party insurers set higher co-pays for brands, patients are reacting by forcibly choosing generic alternatives. Spiers suggests that the economic downturn is going to further drive this demand and further spur prescription abandonment. "Increased unemployment and high numbers of newly uninsured are encouraging patients to look for ways to cut costs," added Spiers. "Choosing a generic over a brand fits right into that mindset."

For more information about Wolters Kluwer Health, visit www.wolterskluwerhealth.com.

About Wolters Kluwer Health

Wolters Kluwer Health (Philadelphia, PA) is a leading provider of information and business intelligence for students, professionals and institutions in medicine, nursing, allied health, pharmacy and the pharmaceutical industry. Major brands include traditional publishers of medical and drug reference tools and textbooks, such as Lippincott Williams & Wilkins and Facts & Comparisons(R); electronic information providers, such as Ovid, UpToDate(R), Medi-Span(R) and ProVation(R) Medical; and pharmaceutical information providers such as Adis International and Source(R).

Wolters Kluwer Health is a division of Wolters Kluwer, a leading global information services and publishing company. The company provides products and services for professionals in the health, tax, accounting, corporate, financial services, legal, and regulatory sectors. Wolters Kluwer had 2008 annual revenues of euro 3.4 billion ($4.9 billion), employs approximately 20,000 people worldwide, and maintains operations in over 35 countries across Europe, North America, Asia Pacific, and Latin America. Wolters Kluwer is headquartered in Amsterdam, the Netherlands. Its shares are quoted on Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices. Visit www.wolterskluwer.com for information about our market positions, customers, brands, and organization.

About Source

Source(R) is a leading provider of market data and analytics for pharmaceutical and biopharmaceutical manufacturers to make decisions and recommendations with confidence, as well as pursue market opportunities for their products. Source offers comprehensive patient and physician-level prescribing and usage data to provide manufacturers with a unique set of more actionable information than is otherwise available. Source is part of Wolters Kluwer Health, a leading provider of information and business intelligence for students, professionals and institutions in medicine, nursing, allied health, pharmacy and the pharmaceutical industry.

    Contact: Tom Kivett
             Kivett & Company Communications
             (212) 727-2935
             tkivett@kivettandco.com


'/>"/>
SOURCE Wolters Kluwer Health
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Prophylactic cranial irradiation in small cell lung cancer significantly increases survival
2. Amid Improving Life Expectancy Rates, Risk of Premature Death is Still Significant for Americans, New Study Shows
3. Elliott Extremely Dissatisfied With Genzyme Bid for Bioenvision; Believes Offer Significantly Undervalues Company
4. Study shows adverse drug events reported to the FDA have significantly increased
5. Patent Expiries of Proscar and Flomax/Harnal Will Cause a Significant Decline in Near-Term Sales of Benign Prostatic Hyperplasia Drugs
6. Ericom Provides Significant Cost-Savings for Major New York City Healthcare Organization
7. Rehabilitation significantly underused after heart attack and bypass surgery
8. First significant genetic finding in severe PMS, or PMDD
9. Promising Phase 3 trial results show biologic therapy ustekinumab significantly improved psoriasis
10. National Domestic Violence Hotline Unveils 10-Year Blueprint to Significantly Reduce Domestic Violence in America
11. New Study Shows Arthritis Significantly Limits Millions of Americans Ability to Work
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... , ... January 21, 2017 , ... Seamild, the largest ... the futuristic vision of its owner and founder. As Oat is recognized globally as ... everybody he knows personally as he believes it is a move to sow the ...
(Date:1/21/2017)... (PRWEB) , ... January 21, 2017 , ... ... of Alumni Relations, Dianne Travis-Teague, the electrifying line-up of events for its annual ... alumni, family, friends, and community. “Coming Home 2017” will be held on ...
(Date:1/21/2017)... ... January 21, 2017 , ... Santa Rosa Orthopaedics (SRO) ... located at 167 Lynch Creek Way. The Petaluma office features three comfortable patient ... and rehabilitation services and on-site x-ray services. Two multi-specialist orthopaedic surgeons Dr. ...
(Date:1/21/2017)... ... 2017 , ... The Nobel Biocare™ dental implant company is ... its creos™ line of bone regenerative products. Specifically, the Nobel Biocare™ ... creos™ allo.gain™ bone graft for a variety of bone reconstruction procedures. In addition ...
(Date:1/20/2017)... ... January 20, 2017 , ... A new partnership between ... they no longer use or need, from clothes to couches to dressers and bicycles. ... and take them to the nearest Goodwill donation center through February 28th. , ...
Breaking Medicine News(10 mins):
(Date:1/20/2017)... Research and Markets has announced the addition of ... BUN Creatinine, Electrolyte Testing, HbA1c Testing, Comprehensive Metabolic Panel, Liver Panel, ... 2024" report to their offering. ... The global clinical laboratory testing market is ... of innovative solutions on the grounds of maximum efficiency and minimum ...
(Date:1/20/2017)... BUFFALO, N.Y. , Jan. 20, 2017 /PRNewswire/ ... health programs, has announced the launch of an ... to new guidelines on opioids and helps stem ... Opioids are often prescribed to treat chronic non-cancer ... disease) despite serious risks and lack of evidence ...
(Date:1/19/2017)... NEW YORK , Jan. 19, 2017 /PRNewswire/ ... reach USD 233.7 billion by 2025, according to ... The market is anticipated to be predominantly driven ... companies, resulting into the large-scale production of new ... widen the influx of drugs at an unprecedented ...
Breaking Medicine Technology: